Darexaban

Astellas Pharma Inc. Discontinues Development of Darexaban (YM150),an Oral Direct Factor Xa Inhibitor

Tokyo, September 28, 2011 - Astellas Pharma Inc. (Tokyo:4503 “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development code name: YM150, “darexaban”), an oral direct Factor Xa inhibitor for all indications.
 

No votes yet
Syndicate content